KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Depreciation & Amortization (CF) (2018 - 2025)

Historic Depreciation & Amortization (CF) for BioNTech SE (BNTX) over the last 8 years, with Q2 2025 value amounting to $57.7 million.

  • BioNTech SE's Depreciation & Amortization (CF) rose 743.11% to $57.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $279.5 million, marking a year-over-year increase of 2210.98%. This contributed to the annual value of $318.4 million for FY2024, which is 6137.72% up from last year.
  • BioNTech SE's Depreciation & Amortization (CF) amounted to $57.7 million in Q2 2025, which was up 743.11% from $45.0 million recorded in Q1 2025.
  • Over the past 5 years, BioNTech SE's Depreciation & Amortization (CF) peaked at $176.7 million during Q4 2024, and registered a low of $15.68 during Q1 2021.
  • Over the past 5 years, BioNTech SE's median Depreciation & Amortization (CF) value was $38.5 million (recorded in 2022), while the average stood at $47.7 million.
  • Over the last 5 years, BioNTech SE's Depreciation & Amortization (CF) had its largest YoY gain of 19957050007.42% in 2021, and its largest YoY loss of 9999.98% in 2021.
  • BioNTech SE's Depreciation & Amortization (CF) (Quarter) stood at $29.7 million in 2021, then fell by 0.52% to $29.6 million in 2022, then surged by 186.56% to $84.8 million in 2023, then surged by 108.47% to $176.7 million in 2024, then tumbled by 67.34% to $57.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $57.7 million in Q2 2025, compared to $45.0 million in Q1 2025 and $176.7 million in Q4 2024.